Growing Revenue Cerus has demonstrated robust revenue growth, reaching between $100 million to $250 million, supported by strong global sales efforts and increasing awareness of the benefits of pathogen reduction technologies. This presents a solid foundation for expanding product adoption and upselling to existing customers.

Global Regulatory Approvals With the INTERCEPT Blood System holding both CE mark and FDA approval for key blood components, Cerus is well-positioned to capitalize on international markets, particularly in regions emphasizing blood safety, opening opportunities for expansion into new geographies.

Strategic Industry Engagement Recent industry workshops and formal recommendations from national blood safety bodies, such as in Germany, bolster Cerus’s credibility and create potential avenues to collaborate with blood authorities and hospitals seeking evidence-based safety improvements.

Expanding Product Pipeline Cerus's late-stage clinical development of the INTERCEPT red blood cell system signals future revenue opportunities and increased market penetration, especially if regulatory approvals are secured, allowing for broader deployment of pathogen-reduced blood components.

Market Positioning Given Cerus’s focus on blood safety and its specialized technology, there is significant potential to partner with large medical device and biotech distributors, as well as hospitals and blood centers aiming to modernize their blood supply chains with validated pathogen reduction solutions.